Novel Exenatide Analogs with Peptidic Albumin Binding Domains: Potent Anti-Diabetic Agents with Extended Duration of Action

• Odile E. Levy,

  Affiliation Amylin Pharmaceuticals LLC, San Diego, California, United States of America

  ⨯
• Carolyn M. Jodka,

  Affiliation Amylin Pharmaceuticals LLC, San Diego, California, United States of America

  ⨯
• Shijun Steven Ren,

  Affiliation Amylin Pharmaceuticals LLC, San Diego, California, United States of America

  ⨯
• Lala Mamedova,

  Affiliation Amylin Pharmaceuticals LLC, San Diego, California, United States of America

  ⨯
• Abhinandini Sharma,

  Affiliation Amylin Pharmaceuticals LLC, San Diego, California, United States of America

  ⨯
• Manoj Samant,

  Affiliation Amylin Pharmaceuticals LLC, San Diego, California, United States of America

  ⨯
• Lawrence J. D’Souza,

  Affiliation Amylin Pharmaceuticals LLC, San Diego, California, United States of America

  ⨯
• Christopher J. Soares,

  Affiliation Amylin Pharmaceuticals LLC, San Diego, California, United States of America

  ⨯
• Diane R. Yuskin,

  Affiliation Amylin Pharmaceuticals LLC, San Diego, California, United States of America

  ⨯
• Li Jenny Jin,

  Affiliation Amylin Pharmaceuticals LLC, San Diego, California, United States of America

  ⨯
• David G. Parkes,

  Affiliation Amylin Pharmaceuticals LLC, San Diego, California, United States of America

  ⨯
• Krystyna Tatarkiewicz,

  Affiliation Amylin Pharmaceuticals LLC, San Diego, California, United States of America

  ⨯
• Soumitra S. Ghosh

  * E-mail: sghosh1@san.rr.com

  Affiliation Amylin Pharmaceuticals LLC, San Diego, California, United States of America

  ⨯